33 related articles for article (PubMed ID: 11564090)
1. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation.
Cremers S; Schoemaker R; Bredius R; den Hartigh J; Ball L; Twiss I; Vermeij P; Vossen J
Br J Clin Pharmacol; 2002 Apr; 53(4):386-9. PubMed ID: 11966670
[TBL] [Abstract][Full Text] [Related]
2. Optimal Once-Daily Busulfan Administration in Pediatric Patients: A Simulation-Based Investigation of Intravenous Infusion Times.
Kim Y; Moon S; Rhee SJ
Drug Des Devel Ther; 2024; 18():871-879. PubMed ID: 38524879
[TBL] [Abstract][Full Text] [Related]
3. Limited Sampling Strategy Using End of Infusion and Six-Hour Concentrations Overestimates Intravenous Busulfan Clearance Compared With Standard Six-Point Sampling in Hematopoietic Stem Cell Transplant Patients.
Salman BM; Al Riyami IM; AalHamad AH; Al-Khabori M
Ther Drug Monit; 2023 Dec; 45(6):766-771. PubMed ID: 37488745
[TBL] [Abstract][Full Text] [Related]
4. Unique Pharmacokinetics for Oral Tacrolimus Administration After Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia With Shwachman-Diamond Syndrome.
Inoue Y; Uemura Y; Kosugi S; Kanno M; Sano F
Am J Ther; 2024 May-Jun 01; 31(3):e318-e319. PubMed ID: 37831700
[No Abstract] [Full Text] [Related]
5. Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome.
Meadows ME; Chang G; Jones JA; Antin JR; Orav EJ
Arch Clin Neuropsychol; 2013 Jun; 28(4):363-74. PubMed ID: 23391504
[TBL] [Abstract][Full Text] [Related]
6. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
7. Molecular effect of human umbilical cord blood CD34-positive and CD34-negative stem cells and their conjugate in azoospermic mice.
Abd Allah SH; Pasha HF; Abdelrahman AA; Mazen NF
Mol Cell Biochem; 2017 Apr; 428(1-2):179-191. PubMed ID: 28120211
[TBL] [Abstract][Full Text] [Related]
8. Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
Damaj G; Cornillon J; Bouabdallah K; Gressin R; Vigouroux S; Gastinne T; Ranchon F; Ghésquières H; Salles G; Yakoub-Agha I; Gyan E
Bone Marrow Transplant; 2017 Jul; 52(7):941-949. PubMed ID: 28112752
[TBL] [Abstract][Full Text] [Related]
9. Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.
Philippe M; Goutelle S; Guitton J; Fonrose X; Bergeron C; Girard P; Bertrand Y; Bleyzac N
Bone Marrow Transplant; 2016 Jan; 51(1):72-8. PubMed ID: 26389835
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of mouse germ cell-associated genes expression by injection of human umbilical cord mesenchymal stem cells into the testis of chemical-induced azoospermic mice.
Yang RF; Liu TH; Zhao K; Xiong CL
Asian J Androl; 2014; 16(5):698-704. PubMed ID: 24830694
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.
Nagler A; Labopin M; Berger R; Bunjes D; Campos A; Socié G; Kröger N; Goker H; Yakoub-Agha I; Shimoni A; Mohty M; Rocha V
Bone Marrow Transplant; 2014 May; 49(5):628-33. PubMed ID: 24535127
[TBL] [Abstract][Full Text] [Related]
12. Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).
Fadilah SA; Aqilah MP
Stem Cell Rev Rep; 2012 Dec; 8(4):1254-64. PubMed ID: 22836809
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.
Uberti JP; Agovi MA; Tarima S; Haagenson M; Gandham S; Anasetti C; Baker KS; Bolwell BJ; Bornhauser M; Chan KW; Copelan E; Davies SM; Finke J; Hale GA; Kollman C; McCarthy PL; Ratanatharathorn V; Ringdén O; Weisdorf DJ; Rizzo JD
Bone Marrow Transplant; 2011 Jan; 46(1):34-43. PubMed ID: 20400989
[TBL] [Abstract][Full Text] [Related]
14. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
Schuler US; Renner UD; Kroschinsky F; Johne C; Jenke A; Naumann R; Bornhäuser M; Deeg HJ; Ehninger G
Br J Haematol; 2001 Sep; 114(4):944-50. PubMed ID: 11564090
[TBL] [Abstract][Full Text] [Related]
15. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience.
Olavarria E; Kanfer E; Szydlo R; O'Brien S; Craddock C; Apperley J; Goldman J
Br J Haematol; 2000 Mar; 108(4):769-77. PubMed ID: 10792282
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation.
Olavarria E; Hassan M; Eades A; Nilsson C; Timms A; Matthews J; Craddock C; Kanfer E; Apperley J; Goldman J
Leukemia; 2000 Nov; 14(11):1954-9. PubMed ID: 11069031
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
[TBL] [Abstract][Full Text] [Related]
18. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children.
Krivoy N; Hoffer E; Lurie Y; Bentur Y; Rowe JM
Curr Drug Saf; 2008 Jan; 3(1):60-6. PubMed ID: 18690982
[TBL] [Abstract][Full Text] [Related]
19. [Place of hematopoietic stem cell transplantation in the treatment of myelodysplastic syndromes].
Kroschinsky F; Bornhäuser M; Ehninger G
Med Klin (Munich); 2001 Mar; 96(3):135-43. PubMed ID: 11315397
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
